Therapy News and Research

RSS

Sorin launches FDA-approved PARADYM RF family of ICDs and CRT-D devices

Sorin Group, a global medical device company and a leader in the treatment of cardiovascular diseases, announced today at Heart Rhythm 2012, the Heart Rhythm Society's 33rd Annual Scientific Sessions, FDA approval and commercial launch of the PARADYM RF family of implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy (CRT-D) devices.

9 May 2012

eTNS therapy can impact symptoms in pharmacoresistant major depression

Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy.

9 May 2012

Research grants on facioscapulohumeral dystrophy prove useful as genetic basis is found

Businessman Bill Moss’s determination to fight his untreatable muscle-wasting disease may have paid off. Four years ago, Mr Moss, a former Macquarie Bank Executive Director, established a charitable research foundation, FSHD Global, which partly funded the Italian researchers who made the breakthrough.

8 May 2012

Rexahn submits Phase II protocol for Archexin clinical study for ovarian cancer

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that it has submitted a Phase II protocol for the clinical study of Archexin as a treatment of ovarian cancer to the U.S. Food and Drug Administration (FDA).

8 May 2012

Covidien to unveil new OneShot renal denervation system at EuroPCR congress

Covidien, a leading global provider of healthcare products, will unveil its new OneShot renal denervation system at the EuroPCR congress in Paris, France, on May 16, 2012. Adding to the Company's broad and growing vascular therapies portfolio, the OneShot system is designed to treat patients with hypertension who are not responsive to traditional medical therapy.

8 May 2012

FDA approves St. Jude Medical's Assura family of implantable defibrillators

St. Jude Medical, Inc., a global medical device company, today announced U.S. Food and Drug Administration (FDA) approval of its Assura portfolio of implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy defibrillators (CRT-Ds).

8 May 2012

DFG to establish seven new research units

The establishment of six new Research Units and one Clinical Research Unit has been decided by the Joint Committee of the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation). These networks will offer researchers the opportunity to address current and pressing issues in their fields and to pioneer innovative approaches. As all DFG Research Units, the new groups will work across locations and disciplines. Clinical Research Units combine clinical, applied and basic research.

8 May 2012

Breast brachytherapy with strut-based applicator effective for women with DCIS

Breast brachytherapy with a strut-based applicator appears to be an effective treatment for women who have ductal carcinoma in situ (DCIS) of the breast, according to a groundbreaking study presented at the annual meeting of the American Society of Breast Surgeons, held in Phoenix May 2-4.

8 May 2012

Metformin blocks uveitis in laboratory rats

University of Texas Medical Branch at Galveston researchers have discovered that a drug already prescribed to millions of people with diabetes could also have another important use: treating one of the world's leading causes of blindness.

8 May 2012

Schoolyard can become therapeutic landscape for children with autism

A Kansas State University graduate student is creating a schoolyard that can become a therapeutic landscape for children with autism.

8 May 2012

iCAD first quarter total revenue decreases 14% to $6.3 million

iCAD, Inc., an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today reported financial results for the first quarter ended March 31, 2012.

8 May 2012

Soon a single therapy for range of brain diseases like Parkinson’s and Alzheimer’s

In a study, published in Nature, researchers prevented brain cells dying in mice with prion disease. It is hoped the same method for preventing brain cell death could apply in other diseases. The findings are at an early stage, but have been heralded as “fascinating”.

8 May 2012

Can curry really be beneficial for cancer?

Curcumin is found in the spice turmeric has been linked to a range of health benefits. Studies have already shown that it can beat cancer cells grown in a laboratory and benefits have been suggested in stroke and dementia patients as well. Cucurmin, which acts as an antioxidant and has anti-inflammatory properties, has traditionally been used as an alternative remedy for liver disease, digestive disorders, acne and a range of allergies. Some studies have shown it may slow the spread of cancer, boost the effectiveness of chemotherapy and protect healthy cells from the effects of radiotherapy.

8 May 2012

Mini-Lecture Series from ARUP Laboratories

ARUP Laboratories, a national reference laboratory, is pleased to announce its Mini-Lecture Series during the annual Scientific Meeting of the American Pain Society in Honolulu.

8 May 2012

Pall in-line filters can reduce severe complications, length of hospital stay in PICU

A recently published clinical study on infusion therapy indicates in-line filters from Pall Corporation can reduce severe complications and the length of a patient's stay in the pediatric intensive care unit.

From Pall Corporation 8 May 2012

Salix first quarter total product revenue increases 62% to $171.1M

Salix Pharmaceuticals, Ltd. today announced financial and operating results for the first quarter ended March 31, 2012 and other business updates.

8 May 2012

DBS may offer hope for patients with mild Alzheimer's

A study on a handful of people with suspected mild Alzheimer's disease (AD) suggests that a device that sends continuous electrical impulses to specific "memory" regions of the brain appears to increase neuronal activity. Results of the study using deep brain stimulation, a therapy already used in some patients with Parkinson's disease and depression, may offer hope for at least some with AD, an intractable disease with no cure.

8 May 2012

Researchers discover CD19 pathway that leads to lymphoma

Researchers studying the molecular signals that drive a specific type of lymphoma have discovered a key biological pathway leading to this type of cancer. Cancerous cells have been described as being "addicted" to certain oncogenes (cancer-causing genes), and the new research may lay the groundwork for breaking that addiction and effectively treating aggressive types of B cell lymphoma.

8 May 2012

New data from Acucela’s ACU-4429 Phase 2a trial on advanced dry AMD/geographic atrophy

Acucela Inc., a clinical-stage biotechnology company focused on developing new treatments for blinding eye diseases, announced today that the first patient data from the ACU-4429 program were presented during a poster session at The Association for Research in Vision and Ophthalmology (ARVO) 2012 Annual Meeting.

8 May 2012

State roundup: Calif. fight over group homes for seniors; New agency proposed to police disabled care in NY; Conn. retiree health plan expansion could endanger protections

Neighbors were already concerned about the growing number of group homes for the elderly and recovering addicts in the area, many of them for profit. A Times analysis found 24 licensed facilities offering residential care for the elderly within a mile of the proposed project and three more waiting for state approval. It is one of several such clusters that have emerged in Los Angeles County -- including parts of the San Fernando Valley and South Bay -- where families can afford fees that run into thousands of dollars per month. Large swaths of the county's less affluent areas have no such facilities.

8 May 2012